Benign prostatic hyperplasia: a quantitative study about chilean epidemiology
DOI:
https://doi.org/10.52611/confluencia.2024.1115Keywords:
Prostatic hyperplasia, Epidemiology, ChileAbstract
Introduction: Benign prostatic hyperplasia is a common condition in older men, characterised by benign enlargement of prostate volume and associated urinary symptoms. In Chile, the lack of studies on its prevalence makes it difficult to target prevention and treatment strategies. Objective: To describe epidemiologically the hospital discharges for benign prostatic hyperplasia in Chile, considering magnitude and variables of time, place and age. Methodology: To address this gap, a retrospective study was conducted in men nationwide between 2002 and 2019, using public records of hospital discharges for benign prostatic hyperplasia from the Chilean Ministry of Health. Age-adjusted discharge rates were calculated to assess variation over time. Results: A 44,79% decrease in hospital admissions for benign prostatic hyperplasia between 2002 and 2019 was revealed. The month with the lowest number of hospital admissions was February and the highest was June. The region with the highest rate of discharges was Arica y Parinacota, being 1,92 times the national rate and 3,16 times that of O'Higgins. In addition, a progressive increase in discharge rates with age was observed. Discussion and Conclusion: Given the scarce national literature on epidemiology, hospital discharges are used to understand epidemiological behaviour. It is crucial to collect incidence and prevalence data to guide public health strategies. Benign prostatic hyperplasia increases with age, while Disability Adjusted Life Years and socioeconomic status are inversely correlated, reflecting longer life expectancy and better health in high socioeconomic status countries.
Downloads
References
Mitchell RN, Kumar V, Abbas AK, Aster JC. Compendio de Robbins y Cotran. Patología estructural y funcional [Internet]. USA: Elsevier Health Sciences; 2017 [citado el 1 de mayo 2024]. Disponible en: https://medicina2023.wordpress.com/wp-content/uploads/2020/03/compendio-de-robbins-y-cotran-patologia-estructural-y-funcional-9a-edicion_booksmedicos.org_.pdf
McVary KT. Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia [Internet]. Waltham, MA: UpToDate; 2019 [citado el 1 de mayo 2024]. Disponible en: https://medilib.ir/uptodate/show/6889
Aurilio G, Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, et al. Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications. Cells [Internet]. 2020 [citado el 1 de mayo 2024];9(12):2653. Disponible en: https://doi.org/10.3390/cells9122653
Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia–what do we know? BJU [Internet]. 2021 [citado el 1 de mayo 2024];127(4):389-99. Disponible en: https://doi.org/10.1111/bju.15229
Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urologic Clinics [Internet]. 2016 [citado el 1 de mayo 2024]1;43(3):289-97. Disponible en: https://doi.org/10.1016/j.ucl.2016.04.001
Robert G, De La Taille A, Descazeaud A. Données épidémiologiques en rapport avec la prise en charge de l’HBP. Prog Urol [Internet]. 2018 [citado el 1 de mayo 2024];28(15):803-12. Disponible en: https://doi.org/10.1016/j.purol.2018.08.005
Ng M, Leslie SW, Baradhi KM. Benign prostatic hyperplasia. StatPearls [Internet]. 2024 [citado el 1 de mayo 2024]. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32644346/
Preciado-Estrella DA, Kaplan SA, Iturriaga-Goyón E, Ramón-Trejo E, Mayorga-Gómez E, Auza-Benavides A. Comparación del Índice Internacional de Síntomas Prostáticos versus Escala Visual Análoga Gea® para la evaluación de los síntomas de la vía urinaria inferior. Rev Mex Urol [Internet]. 2017 [citado el 1 de mayo 2024];77(5):372-82. Disponible en: https://doi.org/10.24245/revmexurol.v77i5.1125
Fowke JH, Munro H, Signorello LB, Blot WJ, Penson DF, Urologic Diseases of America Project. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med [Internet]. 2011 [citado el 1 de mayo 2024];26:1305-10. Disponible en: https://doi.org/10.1007/s11606-011-1776-8
Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal Jr DE, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol [Internet]. 2019 [citado el 1 de mayo 2024];8(5):529. Disponible en: https://doi.org/10.21037/tau.2019.10.01
McVary KT. Epidemiology and pathophysiology of benign prostatic hyperplasia [Internet]. USA: UpToDate; 2022 [citado el 1 de mayo 2024]. Disponible en: https://www.uptodate.com/contents/epidemiology-and-pathophysiology-of-benign-prostatic-hyperplasia
Zambrano N, Palma C. Tratamiento de la hiperplasia prostática benigna y de la disfunción eréctil por el médico general. Rev Méd Clín Las Condes [Internet]. 2018 [citado el 1 de mayo 2024];29(2):180-92. Disponible en: https://doi.org/10.1016/j.rmclc.2018.01.003
Van Den Eeden SK, Shan J, Jacobsen SJ, Aaronsen D, Haque R, Quinn VP, et al. Evaluating racial/ethnic disparities in lower urinary tract symptoms in men. J Urol [Internet]. 2012 [citado el 1 de mayo 2024];187(1):185-9. Disponible en: https://doi.org/10.1016/j.juro.2011.09.043
Institute for Health Metrics and Evaluation. Global Burden of Disease 2021. Washington: IHME; 2024 [citado el 1 de mayo 2024]. Disponible en: https://www.healthdata.org/sites/default/files/2024-05/GBD_2021_Booklet_FINAL_2024.05.16.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Revista Confluencia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.